



SPAFID
CONNECT

Informazione Regolamentata n. 0957-24-2022	Data/Ora Ricezione 21 Aprile 2022 12:48:19	Euronext Milan
--	---	----------------

Societa' : DiaSorin

Identificativo : 160739

Informazione
Regolamentata

Nome utilizzatore : DIASORINN01 - Ulisse Spada - Valerio
Vaccarone

Tipologia : 2.5

Data/Ora Ricezione : 21 Aprile 2022 12:48:19

Data/Ora Inizio : 21 Aprile 2022 12:48:21

Diffusione presunta

Oggetto : RECTIFICATION - Communication on total
amount of voting rights.

Testo del comunicato

Replaces the previous press release published today.

DIASORIN: COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

Saluggia, April 21, 2022 – In accordance with Article 85-bis paragraph 4-bis, of Consob Regulation no. 11971/1999 DiaSorin (FTSE MIB: DIA) hereby communicates the total amount of the voting rights, together with the number of shares making up the share capital, as of April 20, 2022 (record date):

	Number of shares making up share capital	No. of voting rights	Euro
Total amount, of which:	55,948,257	88,444,072	55,948,257
Ordinary shares without increased voting rights ISIN IT0003492391 (regular dividend) Current coupon: no. 16	23,452,442	23,452,442	-
Ordinary shares with increased voting rights ISIN IT0005188385 (regular dividend) Current coupon: no. 16	32,495,815	64,991,630	-

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Emanuela Salvini
Investor Relator
Tel: +39.0161.487567
emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasoringroup.com

Fine Comunicato n.0957-24

Numero di Pagine: 3